FOR IMMEDIATE RELEASE — 23 June 2025

Golden Age Health and Innostellar Biotherapeutics Sign Exclusive 10-Year Collaboration to Accelerate LX-101 Gene Therapy for Inherited Retinal Dystrophies due to RPE 65 gene mutation in Mainland China

Golden Age Health Pte. Ltd. ("**GAH**") and **Innostellar Biotherapeutics Co., Ltd.** ("**Innostellar**") today announced an **exclusive ten-year Promotion Services Agreement** that grants GAH sole rights to commercialise and promote Innostellar's first-in-class gene-therapy candidate **LX-101** across Mainland China. Leveraging its full-spectrum patient-focused launch platform covering disease and medical education, market access and patient support to address the unmet needs along the patient journey such as disease awareness, timely diagnosis and treatment, treatment accessibility and affordability. GAH, along with Innostellar will act with urgency to bring this life-changing therapy to patients affected by inherited retinal dystrophies due to RPE 65 gene mutation in Mainland China so they can "*see the future, clearly"*.

"Partnering with Innostellar positions GAH at the forefront of gene therapy in China's rapidly expanding ophthalmology market," said **Francis Wan, Chief Executive Officer of Golden Age Health**. "Our integrated approach aims to deliver sight-saving innovation to patients swiftly and comprehensively."

Dr Wang Fenghua, Founder & CEO of Innostellar, added: "By joining forces with GAH, we can ensure LX-101 reaches patients across China rapidly and—crucially—at prices families can afford, thanks to efficiencies gained through local development and manufacturing. Improving patient access lies at the heart of our mission

Dr Shibeshih Mitiku Belachew, MD PhD, Scientific and Medical Advisor of Golden Age Health, commented: "LX-101 gene therapy has the potential to convert a relentlessly progressive blinding disorder into a treatable condition. Our medical-affairs and real-world data generation teams will work with investigators, payers and patient groups to advance the robust evidence base needed to support broad, affordable access to this sight-restoring medicine."

About Inherited Retinal Dystrophies

Inherited retinal dystrophies (IRDs)—including **retinitis pigmentosa (RP)**—are genetic disorders that progressively destroy photoreceptors, leading to severe vision impairment or blindness, often from childhood. RP affects approximately **1 in 3,000–4,000 people worldwide** and is officially listed in China's **National Rare Disease Catalog** (first list, 2018), underscoring the country's commitment to improving outcomes for affected patients.

About LX-101

LX-101 is an adeno-associated-virus (AAV) gene therapy delivering a functional **RPE65** gene directly to retinal cells, aiming to restore the visual cycle in patients with biallelic RPE65-mutation IRDs. The programme is in **Phase III clinical development in China**, with top-line results expected in **Q4 2025** and initiate NMPA New Drug Application soon after. If approved, LX-

101 would provide eligible patients with a single-dose, durable treatment designed to halt—or potentially reverse—vision loss.

About Golden Age Health

Golden Age Health is a specialty pharmaceutical company dedicated to redefining patient access to medicine across China, Asia-Pacific and beyond. Headquartered in Singapore, GAH pairs data-driven market-access expertise with deep medical-affairs and RWE capabilities to bring high-impact therapies to underserved populations.

About Innostellar Biotherapeutics

Innostellar Biotherapeutics is a Shanghai-based biotechnology firm advancing innovative gene-therapy medicines for ocular and other genetic diseases and chronic diseases. Its pipeline is led by LX-101, the first gene therapy of its kind to enter late-stage development in China.

Media & Investor Contacts

Golden Age Health	**Innostellar Biotherapeutics**
Media/IR: info@gahbioventures.com	**Media/IR:** ir@innostellar.cn

---

Forward-Looking Statements
This release contains forward-looking statements, including expectations regarding clinical development, regulatory approvals and commercial launches. These statements involve risks and uncertainties that may cause actual outcomes to differ materially.

FOR IMMEDIATE RELEASE — 23 June 2025

Golden Age Health 与 Innostellar Biotherapeutics 签署独家十年合作协议，加速 LX-101 基因疗法在中国大陆治疗由 RPE65 基因突变引起的遗传性视网膜营养不良

Golden Age Health Pte. Ltd.（“GAH”）与 Innostellar Biotherapeutics Co., Ltd.（“Innostellar”）今日宣布签署一项为期十年的独家《推广服务协议》。根据协议，Golden Age Health 将获得 Innostellar 在中国大陆独家商业化推广其首创新药（FIC）基因疗法候选药物 LX-101 的权利。Golden Age Health 将利用其覆盖疾病与医学教育、市场准入及患者支持的全方位患者服务平台，致力于解决患者旅程中的未满足需求，如疾病认知、及时诊断与治疗、治疗可及性与可负担性。Golden Age Health 将与 Innostellar 通力合作，迅速将这一改变生命的疗法带给中国大陆受 RPE65 基因突变引起的遗传性视网膜营养不良影响的患者，让他们能够“看见清晰未来”。

“与 Innostellar 合作，使 Golden Age Health 站在了中国快速扩张的眼科市场基因疗法领域的前沿，” Golden Age Health 首席执行官 Francis Wan 表示，“我们一体化的方法旨在快速、全面地将拯救视力的创新疗法带给患者。”

Innostellar Biotherapeutics 创始人兼首席执行官 Wang Fenghua 博士补充道：“通过与 Golden Age Health 强强联手，加上本地化开发和生产带来的效率提升，我们能够确保 LX-101 快速惠及中国各地患者，并且至关重要的是，其价格是家庭可负担的。改善患者可及性是我们使命的核心。”

Golden Age Health 科学及医学顾问 Dr. Shibeshih Mitiku Belachew, MD PhD 评论道：“LX-101 基因疗法有潜力将一种持续进展的致盲性疾病转变为可治疗的疾病。我们的医学事务和真实世界数据研究团队将与研究者、支付方及患者组织合作，共同推进建立所需的坚实证据基础，以支持广泛、可负担地获得这种视力恢复疗法。”

关于遗传性视网膜营养不良

遗传性视网膜营养不良（IRDs）——包括视网膜色素变性（RP）——是一类遗传性疾病，会逐步破坏感光细胞，导致严重的视力损害或失明，通常从儿童期开始发病。RP 在全球范围内影响约每 3000–4000 人中的一人，并被正式列入中国《第一批罕见病目录》（2018 年），这体现了中国对改善受影响患者预后的承诺。

关于 LX-101

LX-101 是一种腺相关病毒（AAV）基因疗法，旨在将功能性 RPE65 基因递送至视网膜细胞，以恢复双等位基因 RPE65 突变遗传性视网膜营养不良（IRD）患者的视觉循环。该疗法目前正在中国进行 III 期临床试验开发，关键数据预计将于 2025 年第四季度公布，后续将积极向中国国家药品监督管理局（NMPA）提交新药上市申请（NDA）。若获批，LX-101 将为符合条件的患者提供一种单次给药、疗效持久的治疗方案，旨在阻止或可能逆转视力丧失。

关于 Golden Age Health

Golden Age Health 是一家专科制药公司，致力于重新定义中国、亚太及其他地区患者获得药物的途径。公司总部位于新加坡，将数据驱动的市场准入专业知识与深厚的医学事务及真实世界证据（RWE）能力相结合，为服务不足的人群带来具有重大影响的疗法。

关于 Innostellar Biotherapeutics

Innostellar Biotherapeutics 是一家总部位于上海的生物技术公司，致力于开发治疗眼部及其他遗传性和慢性疾病的创新基因疗法药物。其研发管线由 LX-101 领衔，这是中国首个进入后期开发阶段的同类基因疗法。